MultiplexDX is one of the most innovative biotech corporations, created to bring revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The U.S. site is located in close proximity to the National Institutes of Health as well as the Food and Drug Administration. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
The mission of MultiplexDX is to eliminate cancer misdiagnosis by creating reliable, 100% accurate, quantitative and affordable diagnostic tests. MDX’s IP-based solutions combine visualization and sequencing technologies to quantify 7 or more cancer markers to give each diagnosis a specific “barcode,” which will indicate not only the cancer type but also the duration of personalized treatment for that cancer. As our name suggests, we also use multiplexing; cross-testing and verifying the same result from at least two independent sources. By embedding numbers into pictures and vice-versa, our diagnostics shed light on the patient’s set of cancer markers and profile, enabling oncologists to make evidence-based decisions and prescribe treatment quickly, directly and more accurately.
Based on its proprietary innovative technologies, MultiplexDX offers the following portfolio of product lines and services: RNA sequencing products (barcoded pre-adenylated 3'-adapters, small RNA library preparation kit (in development); FISH products (multi-labeled FISH probes, FullRNAlook kit); Personalized Cancer DX (unique diagnostic services using proprietary Multiplex+TM technology platform, Companion DX projects for offering strategic partnership to Biopharma companies to develop diagnostic tests based on quantification of companion biomarkers, which provide essential information for the safe and effective use of their corresponding drugs);
MultiplexDX products and services offer a variety of cost-effective, innovative and high quality solutions: the most precise sequencing analysis, the simplest and gel-free sequencing protocol, the simplest FISH protocol, the most stable and specific FISH probes, the most precise cancer profiling, the most accurate biomarker quantification. Among the company’s most ambitious plans is the development of hi-definition 3D digital pathology services using a variety of proprietary MultiplexDX technologies.
As every cancer is unique, every patient deserves a personalized diagnosis that leads to tailored, effective, and life-saving treatment. MultiplexDX is launching its next generation of revolutionary diagnostic tests, which can precisely identify and quantify cancer markers. Combining multiplex quantitative RNA fluorescence in situ hybridization (RNA FISH) and RNA sequencing (RNAseq) technologies, MultiplexDX’s biotechnical innovation unifies biomarker quantification, histology, and visualization with single-cell resolution. The unmatched complexity and accuracy of our tests (simultaneous visualization and quantification of seven or more cancer markers) will surpass the limitations of today’s diagnostic tools, and give each diagnosis a specific “barcode” for its cancer type.
MultiplexDX’s products and services will reach beyond the limits of existing visualization methods (e.g. immunohistochemistry (IHC)) and RNA based tests (e.g. RNAseq, qPCR). Conventional visualization assays lack precise quantitative data, while quantitative RNA-based molecular diagnostics miss crucial tissue morphology and localization data. Thus, MultiplexDX’s innovative cancer diagnosing technology will combine the best of these two methods, bringing together localization on a cellular level and quantitative biomarker signal.
Dr. Cekan is an innovative leader with over 15 years of experience at the top research and government institutions. He received his doctorate in chemistry from the University of Iceland. As a Postdoctoral Associate in Prof. Thomas Tuschl’s lab at Rockefeller University, Dr. Cekan developed methodology for the retention of nucleic acids in tissue sections during RNA in situ hybridization and preparation/validation of specific oligonucleotide probes and fluorescent signal amplification processes. He established conditions for innovative diagnostic miRNA/mRNA/ncRNA FISH, immunohistochemistry (IHC), immunofluorescence (IF) and qPCR in paraffin-embedded tissues. Dr. Cekan, along with Prof. Tuschl, invented EDC-based RNA fixation and patented a state-of-the-art RNA FISH method targeting any RNA in the tissues and cell pellets. During his time as an FTE Research Fellow at the National Cancer Institute, Dr. Cekan was part of a research team working on RCC1 and Ran involvement in cell cycle return of normal/cancer cells after DNA damage by triggering ATM signaling and 53BP1 repair and/or terminating ATR/Chk1 DNA damage response (DDR).
Together with Dr. Vladimir Wolf, Dr. Cekan co-founded MultiplexDX, bringing innovative biotechnologies to cancer diagnostic market.
Dr. Wolf has worked for more than 10 years in the biotechnology industry, in positions ranging from scientist to Director of Business Development, and in operations in both U.S. and European markets. He received his doctoral training in molecular biology from the Cancer Institute of Medical Sciences Faculty at the University of Bern, Switzerland, where his primary research focused on signaling pathways involved with mammary gland apoptosis and carcinogenesis. He focused on the same signaling pathways while working at the Laboratory of Cell and Molecular Biology at the National Cancer Institute, USA. During his time at biotech company Trophogen Inc., Dr. Wolf advanced from scientist to Director of Business Development and, as such, played a pivotal role in securing licensing deals with Zoetis, the world’s largest animal health company. During his tenure as a manufacturing scientist at diagnostics company QIAGEN, Dr. Wolf designed and implemented new manufacturing processes in compliance with CGMP regulations. He was also sponsored by QIAGEN to receive his MBA in Business Integration from the University of Wurzburg, Germany.
Dr. Kilián is focusing on consulting of biomedical and biotechnology projects since 2010. In his work he makes use of experience gathered over the years spent at various positions in the area of fundamental and applied research, clinical diagnostics and company management. His knowledge also includes technology transfer, conception and implementation of projects funded by EU structural funds, topics he addressed while working as Managing Director at BioScience Slovakia. Since 2014 he is working as an evaluator of SME Instrument projects from Horizon 2020. He is an EPO certified trainer in the field of intellectual property. He studied Biomedical physics at Comenius University in Bratislava and since 2005 holds a PhD. in Physiology and Biophysics from Université de Sherbrooke in Canada.